{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:56:49Z","timestamp":1782917809092,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herzschr Elektrophys"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Device-detektiertes Vorhofflimmern (DDAF) ist wie klinisches Vorhofflimmern (AF) ebenfalls mit einem erh\u00f6hten Risiko f\u00fcr thrombembolische Ereignisse assoziiert, wobei das Risiko jedoch deutlich geringer auszufallen scheint. Die Wirksamkeit und Sicherheit einer oralen Antikoagulation bei DDAF wurden in zwei gro\u00dfen randomisierten Studien (NOAH-AFNET\u00a06 und ARTESIA [13, 19]) untersucht. Es zeigte sich eine niedrige Rate an isch\u00e4mischen Schlaganf\u00e4llen ohne Antikoagulation (etwa 1\u202f% pro Jahr). Durch eine therapeutische Antikoagulation kann dieses Risiko noch gesenkt werden, allerdings steigt dabei die Gefahr schwerer Blutungen. In dem k\u00fcrzlich ver\u00f6ffentlichten Positionspapier [36] der Deutschen Gesellschaft f\u00fcr Kardiologie wurde die aktuelle Studienlage dargestellt und Expertenempfehlungen zum Umgang mit DDAF gegeben.<\/jats:p>","DOI":"10.1007\/s00399-025-01112-7","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:27:09Z","timestamp":1761751629000},"page":"49-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Device-detektiertes Vorhofflimmern\u00a0\u2013 was nun?","What to do with device-detected atrial fibrillation?"],"prefix":"10.1007","volume":"37","author":[{"given":"Tobias","family":"T\u00f6nnis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Becher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Birkemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Duncker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Gr\u00f6schel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Linz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Straube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arian","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Wachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Zylla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"1112_CR1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2029980","volume":"384","author":"JG Andrade","year":"2021","unstructured":"Andrade\u00a0JG, Wells\u00a0GA, Deyell\u00a0MW et\u00a0al (2021) Cryoablation or drug therapy for initial treatment of atrial fibrillation. N\u00a0Engl J Med 384:305\u2013315","journal-title":"N Engl J Med"},{"key":"1112_CR2","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1093\/eurheartj\/ehae373","volume":"45","author":"N Becher","year":"2024","unstructured":"Becher\u00a0N, Metzner\u00a0A, Toennis\u00a0T et\u00a0al (2024) Atrial fibrillation burden: a\u00a0new outcome predictor and therapeutic target. Eur Heart\u00a0J 45:2824\u20132838","journal-title":"Eur Heart J"},{"key":"1112_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/eurheartj\/ehad771","volume":"45","author":"N Becher","year":"2024","unstructured":"Becher\u00a0N, Toennis\u00a0T, Bertaglia\u00a0E et\u00a0al (2024) Anticoagulation with edoxaban in patients with long atrial high-rate episodes \u2265\u202f24 h. Eur Heart\u00a0J 45:837\u2013849","journal-title":"Eur Heart J"},{"key":"1112_CR4","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1016\/j.jacc.2014.04.019","volume":"63","author":"EI Charitos","year":"2014","unstructured":"Charitos\u00a0EI, Purerfellner\u00a0H, Glotzer\u00a0TV et\u00a0al (2014) Clinical classifications of atrial fibrillation poorly reflect its temporal persistence: insights from 1,195 patients continuously monitored with implantable devices. J\u00a0Am Coll Cardiol 63:2840\u20132848","journal-title":"J Am Coll Cardiol"},{"key":"1112_CR5","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1161\/CIRCULATIONAHA.109.875252","volume":"120","author":"SJ Connolly","year":"2009","unstructured":"Connolly\u00a0SJ, Crijns\u00a0HJ, Torp-Pedersen\u00a0C et\u00a0al (2009) Analysis of stroke in ATHENA: a\u00a0placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400\u202fmg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation\/atrial flutter. Circulation 120:1174\u20131180","journal-title":"Circulation"},{"key":"1112_CR6","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/europace\/euaa123","volume":"22","author":"RR De With","year":"2020","unstructured":"De With\u00a0RR, Erkuner\u00a0O, Rienstra\u00a0M et\u00a0al (2020) Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V. Europace 22:1162\u20131172","journal-title":"Europace"},{"key":"1112_CR7","doi-asserted-by":"publisher","first-page":"e036429","DOI":"10.1161\/JAHA.124.036429","volume":"13","author":"HC Diener","year":"2024","unstructured":"Diener\u00a0HC, Becher\u00a0N, Sehner\u00a0S et\u00a0al (2024) Anticoagulation in patients with device-detected atrial fibrillation with and without a\u00a0prior stroke or transient Ischemic attack: the NOAH-AFNET 6 trial. JAHA 13:e36429","journal-title":"JAHA"},{"key":"1112_CR8","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1093\/eurheartj\/ehac471","volume":"43","author":"L Eckardt","year":"2022","unstructured":"Eckardt\u00a0L, Sehner\u00a0S, Suling\u00a0A et\u00a0al (2022) Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4\u00a0trial. Eur Heart\u00a0J 43:4127\u20134144","journal-title":"Eur Heart J"},{"key":"1112_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.tcm.2023.04.001","volume":"34","author":"L Eckardt","year":"2024","unstructured":"Eckardt\u00a0L, Wolfes\u00a0J, Frommeyer\u00a0G (2024) Benefits of early rhythm control of atrial fibrillation. Trends Cardiovasc Med 34:288\u2013294","journal-title":"Trends Cardiovasc Med"},{"key":"1112_CR10","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.jacc.2020.01.052","volume":"75","author":"Y Guo","year":"2020","unstructured":"Guo\u00a0Y, Lane\u00a0DA, Wang\u00a0L et\u00a0al (2020) Mobile health technology to improve care for patients with atrial fibrillation. J\u00a0Am Coll Cardiol 75:1523\u20131534","journal-title":"J Am Coll Cardiol"},{"key":"1112_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1474-4422(21)00067-3","volume":"20","author":"KG Haeusler","year":"2021","unstructured":"Haeusler\u00a0KG, Kirchhof\u00a0P, Kunze\u00a0C et\u00a0al (2021) Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a\u00a0randomised, open-label, multicentre study. Lancet Neurol 20:426\u2013436","journal-title":"Lancet Neurol"},{"key":"1112_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa1105575","volume":"366","author":"JS Healey","year":"2012","unstructured":"Healey\u00a0JS, Connolly\u00a0SJ, Gold\u00a0MR et\u00a0al (2012) Subclinical atrial fibrillation and the risk of stroke. N\u00a0Engl J Med 366:120\u2013129","journal-title":"N Engl J Med"},{"key":"1112_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2310234","volume":"390","author":"JS Healey","year":"2024","unstructured":"Healey\u00a0JS, Lopes\u00a0RD, Granger\u00a0CB et\u00a0al (2024) Apixaban for stroke prevention in subclinical atrial fibrillation. N\u00a0Engl J Med 390:107\u2013117","journal-title":"N Engl J Med"},{"key":"1112_CR14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar\u00a0JA, Chung\u00a0MK, Armbruster\u00a0AL et\u00a0al (2024) 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a\u00a0report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines. Circulation 149:e1\u2013e156","journal-title":"Circulation"},{"key":"1112_CR15","doi-asserted-by":"publisher","first-page":"e034758","DOI":"10.1161\/JAHA.123.034758","volume":"13","author":"LS Johnson","year":"2024","unstructured":"Johnson\u00a0LS, Benz\u00a0AP, Shoamanesh\u00a0A et\u00a0al (2024) Residual stroke risk among patients with atrial fibrillation prescribed oral anticoagulants: a\u00a0patient-level meta-analysis from COMBINE AF. JAHA 13:e34758","journal-title":"JAHA"},{"key":"1112_CR16","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.119.041303","volume":"140","author":"RM Kaplan","year":"2019","unstructured":"Kaplan\u00a0RM, Koehler\u00a0J, Ziegler\u00a0PD et\u00a0al (2019) Stroke risk as a\u00a0function of atrial fibrillation duration and CHA(2)DS(2)-VASc score. Circulation 140:1639\u20131646","journal-title":"Circulation"},{"key":"1112_CR17","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/CIRCULATIONAHA.124.071176","volume":"150","author":"K Kemp Gudmundsdottir","year":"2024","unstructured":"Kemp Gudmundsdottir\u00a0K, Svennberg\u00a0E, Friberg\u00a0L et\u00a0al (2024) Randomized invitation to systematic NT-proBNP and ECG screening in 75-year-olds to detect atrial fibrillation: STROKESTOP II. Circulation 150:1837\u20131846","journal-title":"Circulation"},{"key":"1112_CR18","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","volume":"383","author":"P Kirchhof","year":"2020","unstructured":"Kirchhof\u00a0P, Camm\u00a0AJ, Goette\u00a0A et\u00a0al (2020) Early rhythm-control therapy in patients with atrial fibrillation. N\u00a0Engl J Med 383:1305\u20131316","journal-title":"N Engl J Med"},{"key":"1112_CR19","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1056\/NEJMoa2303062","volume":"389","author":"P Kirchhof","year":"2023","unstructured":"Kirchhof\u00a0P, Toennis\u00a0T, Goette\u00a0A et\u00a0al (2023) Anticoagulation with edoxaban in patients with atrial high-rate episodes. N\u00a0Engl J Med 389:1167\u20131179","journal-title":"N Engl J Med"},{"key":"1112_CR20","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/europace\/euaa298","volume":"23","author":"KH Kuck","year":"2021","unstructured":"Kuck\u00a0KH, Lebedev\u00a0DS, Mikhaylov\u00a0EN et\u00a0al (2021) Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST). Europace 23:362\u2013369","journal-title":"Europace"},{"key":"1112_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euae070","author":"D Linz","year":"2024","unstructured":"Linz\u00a0D, Andrade\u00a0JG, Arbelo\u00a0E et\u00a0al (2024) Longer and better lives for patients with atrial fibrillation: the 9th\u00a0AFNET\/EHRA consensus conference. Europace. https:\/\/doi.org\/10.1093\/europace\/euae070","journal-title":"Europace"},{"key":"1112_CR22","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehae225","volume":"45","author":"GYH Lip","year":"2024","unstructured":"Lip\u00a0GYH, Nikorowitsch\u00a0J, Sehner\u00a0S et\u00a0al (2024) Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6\u00a0trial. Eur Heart\u00a0J 45:1733\u20131737","journal-title":"Eur Heart J"},{"key":"1112_CR23","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/eurheartj\/ehx731","volume":"39","author":"R Mahajan","year":"2018","unstructured":"Mahajan\u00a0R, Perera\u00a0T, Elliott\u00a0AD et\u00a0al (2018) Subclinical device-detected atrial fibrillation and stroke risk: a\u00a0systematic review and meta-analysis. Eur Heart\u00a0J 39:1407\u20131415","journal-title":"Eur Heart J"},{"key":"1112_CR24","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1093\/eurheartj\/ehv115","volume":"36","author":"DT Martin","year":"2015","unstructured":"Martin\u00a0DT, Bersohn\u00a0MM, Waldo\u00a0AL et\u00a0al (2015) Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart\u00a0J 36:1660\u20131668","journal-title":"Eur Heart J"},{"key":"1112_CR25","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1161\/CIRCULATIONAHA.123.067512","volume":"149","author":"WF Mcintyre","year":"2024","unstructured":"Mcintyre\u00a0WF, Benz\u00a0AP, Becher\u00a0N et\u00a0al (2024) Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a\u00a0study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials. Circulation 149:981\u2013988","journal-title":"Circulation"},{"key":"1112_CR26","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1161\/CIRCULATIONAHA.124.069903","volume":"150","author":"WF Mcintyre","year":"2024","unstructured":"Mcintyre\u00a0WF, Benz\u00a0AP, Healey\u00a0JS et\u00a0al (2024) Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: insights from the ARTESiA trial. Circulation 150:1747\u20131755","journal-title":"Circulation"},{"key":"1112_CR27","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1901183","volume":"381","author":"MV Perez","year":"2019","unstructured":"Perez\u00a0MV, Mahaffey\u00a0KW, Hedlin\u00a0H et\u00a0al (2019) Large-scale assessment of a\u00a0smartwatch to identify atrial fibrillation. N\u00a0Engl J Med 381:1909\u20131917","journal-title":"N Engl J Med"},{"key":"1112_CR28","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/s41591-022-01979-w","volume":"28","author":"KD Rizas","year":"2022","unstructured":"Rizas\u00a0KD, Freyer\u00a0L, Sappler\u00a0N et\u00a0al (2022) Smartphone-based screening for atrial fibrillation: a\u00a0pragmatic randomized clinical trial. Nat Med 28:1823\u20131830","journal-title":"Nat Med"},{"key":"1112_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euae247","author":"E Sandgren","year":"2024","unstructured":"Sandgren\u00a0E, Hermans\u00a0ANL, Gawalko\u00a0M et\u00a0al (2024) Smartphone app-based approximation of time spent with atrial fibrillation and symptoms in patients after catheter ablation: data from the TeleCheck-AF project. Europace. https:\/\/doi.org\/10.1093\/europace\/euae247","journal-title":"Europace"},{"key":"1112_CR30","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1093\/eurheartj\/ehae596","volume":"45","author":"RB Schnabel","year":"2024","unstructured":"Schnabel\u00a0RB, Benezet-Mazuecos\u00a0J, Becher\u00a0N et\u00a0al (2024) Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a\u00a0combined analysis of the NOAH-AFNET 6 and ARTESiA trials. Eur Heart\u00a0J 45:4902\u20134916","journal-title":"Eur Heart J"},{"key":"1112_CR31","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S1474-4422(24)00037-1","volume":"23","author":"DJ Seiffge","year":"2024","unstructured":"Seiffge\u00a0DJ, Cancelloni\u00a0V, Raber\u00a0L et\u00a0al (2024) Secondary stroke prevention in people with atrial fibrillation: treatments and trials. Lancet Neurol 23:404\u2013417","journal-title":"Lancet Neurol"},{"key":"1112_CR32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S1474-4422(24)00475-7","volume":"24","author":"A Shoamanesh","year":"2025","unstructured":"Shoamanesh\u00a0A, Field\u00a0TS, Coutts\u00a0SB et\u00a0al (2025) Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a\u00a0history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial. Lancet Neurol 24:140\u2013151","journal-title":"Lancet Neurol"},{"key":"1112_CR33","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/S0140-6736(21)01698-6","volume":"398","author":"JH Svendsen","year":"2021","unstructured":"Svendsen\u00a0JH, Diederichsen\u00a0SZ, Hojberg\u00a0S et\u00a0al (2021) Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a\u00a0randomised controlled trial. Lancet 398:1507\u20131516","journal-title":"Lancet"},{"key":"1112_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euad176","author":"E Svennberg","year":"2023","unstructured":"Svennberg\u00a0E, Caiani\u00a0EG, Bruining\u00a0N et\u00a0al (2023) The digital journey: 25\u00a0years of digital development in electrophysiology from an Europace perspective. Europace. https:\/\/doi.org\/10.1093\/europace\/euad176","journal-title":"Europace"},{"key":"1112_CR35","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(21)01637-8","volume":"398","author":"E Svennberg","year":"2021","unstructured":"Svennberg\u00a0E, Friberg\u00a0L, Frykman\u00a0V et\u00a0al (2021) Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a\u00a0multicentre, parallel group, unmasked, randomised controlled trial. Lancet 398:1498\u20131506","journal-title":"Lancet"},{"key":"1112_CR36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s12181-025-00750-y","volume":"19","author":"T T\u00f6nnis","year":"2025","unstructured":"T\u00f6nnis\u00a0T, Birkemeyer\u00a0R, Duncker\u00a0D et\u00a0al (2025) DGK-Positionspapier zum Umgang mit Device-detektiertem Vorhofflimmern (DDAF). Kardiologie 19:270\u2013284. https:\/\/doi.org\/10.1007\/s12181-025-00750-y","journal-title":"Kardiologie"},{"key":"1112_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1177\/23969873221139410","volume":"8","author":"G Tsivgoulis","year":"2023","unstructured":"Tsivgoulis\u00a0G, Palaiodimou\u00a0L, Triantafyllou\u00a0S et\u00a0al (2023) Prolonged cardiac monitoring for stroke prevention: a\u00a0systematic review and meta-analysis of randomized-controlled clinical trials. Eur Stroke\u00a0J 8:106\u2013116","journal-title":"Eur Stroke J"},{"key":"1112_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ahj.2023.06.016","volume":"265","author":"T Uhe","year":"2023","unstructured":"Uhe\u00a0T, Wasser\u00a0K, Weber-Kruger\u00a0M et\u00a0al (2023) Intensive heart rhythm monitoring to decrease ischemic stroke and systemic embolism-the Find-AF 2\u00a0study-rationale and design. Am Heart\u00a0J 265:66\u201376","journal-title":"Am Heart J"},{"key":"1112_CR39","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/eurheartj\/ehx042","volume":"38","author":"IC Van Gelder","year":"2017","unstructured":"Van Gelder\u00a0IC, Healey\u00a0JS, Crijns\u00a0H et\u00a0al (2017) Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart\u00a0J 38:1339\u20131344","journal-title":"Eur Heart J"},{"key":"1112_CR40","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC van Gelder","year":"2024","unstructured":"van Gelder\u00a0IC, Rienstra\u00a0M, Bunting\u00a0KV et\u00a0al (2024) 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS). Eur Heart\u00a0J 45:3314\u20133414","journal-title":"Eur Heart J"},{"key":"1112_CR41","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ahj.2017.12.007","volume":"197","author":"A Verma","year":"2018","unstructured":"Verma\u00a0A, Ha\u00a0ACT, Kirchhof\u00a0P et\u00a0al (2018) The optimal anti-coagulation for enhanced-risk patients post-catheter ablation for atrial fibrillation (OCEAN) trial. Am Heart\u00a0J 197:124\u2013132","journal-title":"Am Heart J"},{"key":"1112_CR42","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa2408308","volume":"392","author":"OM Wazni","year":"2024","unstructured":"Wazni\u00a0OM, Saliba\u00a0WI, Nair\u00a0DG et\u00a0al (2024) Left atrial appendage closure after ablation for atrial fibrillation. N\u00a0Engl J Med 392:1277\u20131287","journal-title":"N Engl J Med"},{"key":"1112_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tcm.2024.04.001","volume":"35","author":"FK Wegner","year":"2025","unstructured":"Wegner\u00a0FK, Eckardt\u00a0L (2025) Thromboembolic risk and oral anticoagulation in subclinical atrial fibrillation. Trends Cardiovasc Med 35:1\u20137","journal-title":"Trends Cardiovasc Med"},{"key":"1112_CR44","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1056\/NEJMoa2101897","volume":"384","author":"RP Whitlock","year":"2021","unstructured":"Whitlock\u00a0RP, Belley-Cote\u00a0EP, Paparella\u00a0D et\u00a0al (2021) Left atrial appendage occlusion during cardiac surgery to prevent stroke. N\u00a0Engl J Med 384:2081\u20132091","journal-title":"N Engl J Med"},{"key":"1112_CR45","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/eurheartj\/ehab593","volume":"43","author":"S Willems","year":"2022","unstructured":"Willems\u00a0S, Borof\u00a0K, Brandes\u00a0A et\u00a0al (2022) Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4\u00a0trial. Eur Heart\u00a0J 43:1219\u20131230","journal-title":"Eur Heart J"}],"container-title":["Herzschrittmachertherapie + Elektrophysiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00399-025-01112-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00399-025-01112-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00399-025-01112-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:33:15Z","timestamp":1782916395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00399-025-01112-7"}},"subtitle":["Executive Summary des DGK-Positionspapiers","Executive summary of the position paper of the German Society\nof Cardiology"],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1112"],"URL":"https:\/\/doi.org\/10.1007\/s00399-025-01112-7","relation":{},"ISSN":["0938-7412","1435-1544"],"issn-type":[{"value":"0938-7412","type":"print"},{"value":"1435-1544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0T\u00f6nnis\n                      ist als Berater f\u00fcr Medtronic und Boston Scientific t\u00e4tig und erhielt Referentenhonorare von Medtronic.\n                      N.\u00a0Becher\n                      erhielt Vortragshonorare von Medtronic und Abbott sowie eine Weiterbildungsf\u00f6rderung von Biotronik.\n                      R.\u00a0Birkemeye\n                      r Beratert\u00e4tigkeit f\u00fcr Biotronik, Preventicus, Honorare von Astra, Bayer, Biotronik, Boehringer, BMS, Chiesi, Daiichi Sankyo und Pfizer.\n                      D.\u00a0Duncker\n                      Beratert\u00e4tigkeit f\u00fcr Medtronic, BMS\/Pfizer, Cardiomatics, Sanofi, Honorare von Abbott, AstraZeneca, Biotronik, Zoll, Pfizer, Boehringer Ingelheim, Boston Scientific, BMS, CVRx, Medtronic, Drittmittel von Zoll, Roche.\n                      L.\u00a0Eckardt\n                      Gelegentliche Vortragst\u00e4tigkeit f\u00fcr pharmazeutische Unternehmen und medizinische Unternehmen.\n                      K.\u00a0Gr\u00f6schel\n                      Vortragst\u00e4tigkeit f\u00fcr Boehringer Ingelheim, Bristol-Myers Squibb GmbH & Co. KGaA, Pfizer Pharma GmbH.\n                      D.\u00a0Linz\n                      gibt keine Interessenskonflikte an.\n                      C.\u00a0Meyer\n                      Beratert\u00e4tigkeit f\u00fcr Biotronik, Biosense Webster, Boston Scientific, Philips Research Europe, Honorare von Abbott, Astra Zeneca, Bayer, Biotronik, BMS, Boehringer Ingelheim, Boston Scientific, Daiichi Sankyo, Pfizer, Drittmittel von Deutsches Zentrum f\u00fcr Herz-Kreislaufforschung Interreg Boston Scientific.\n                      F.\u00a0Straube\n                      gibt keine Interessenskonflikte an.\n                      A.\u00a0Sultan\n                      Beratert\u00e4tigkeit f\u00fcr Abbott, J&J, Medtronic und BSC, Honorare von Abbott, J&J, Medtronic und BSC.\n                      R.\u00a0Wachter\n                      Beratert\u00e4tigkeit f\u00fcr Pharmacosmos, Medtronic, Novartis, Servier, Honorare von BMS, Boehringer Ingelheim, CVRx, Daiichi, Sankyo, Medtronic, Novartis, Pfizer, Sciarc, Vifor, iRhythm Technologies, Drittmittel von Bundesministerium f\u00fcr Bildung und Forschung, Europ\u00e4ische Union, Medtronic, Deutsches Zentrum f\u00fcr Herz\u2011\/Kreislaufforschung, Deutsche Forschungsgemeinschaft.\n                      M.\u00a0Zylla\n                      Vortragshonorare von Medtronic, Boston Scientific, Bayer Vital, Pfizer, Abbott, Zoll CMS; Drittmittel von Johnson and Johnson und DZHK.\n                      P.\u00a0Kirchhof\n                      erh\u00e4lt oder erhielt Unterst\u00fctzung f\u00fcr Forschungsprojekte von: European Union AFFECT-AF (grant agreement 847770), MAESTRIA (grant agreement 965286), British Heart Foundation (PG\/20\/22\/35093; AA\/18\/2\/34218), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, grant numbers DZHK FKZ 81X2800182, 81Z0710116, and 81Z0710110), German Research Foundation (Ki 509167694), Leducq Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}